Needham Lowers Rhythm Pharmaceuticals Price Target to $114 From $130
Needham cut its price target on Rhythm Pharmaceuticals shares to $114 from $130, according to Dow Jones Newswires, which cited Benzinga's ratings data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Needham has lowered its price target on Rhythm Pharmaceuticals (RYTM) to $114 per share from $130, according to Dow Jones Newswires. The figures come from Benzinga's analyst ratings data.
The revision reflects only one brokerage's forecast and includes no new information about the company's operations.
why it matters
A target change like this reflects a single brokerage's view and does not by itself signal a shift in the company's fundamentals. Investors usually weigh such moves against the broader analyst consensus.
tags
instruments
sources
- Rhythm Pharmaceuticals Price Target Cut to $114.00/Share From $130.00 by Needham — Dow Jones Newswires, 3 November 2026 at 20:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗